ESSA Pharma (EPIX) is a Canadian developer of therapies directed specifically at prostate cancer. This is interesting because it is quite rare to see a biotech that's this focused, and that makes it ...
ESSA Pharma Inc EPIX is developing EPI-7386 as a treatment for prostate cancer. It is a member of a novel class of compounds known as ‘anitens', which specifically target the androgen receptor (AR).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results